Superbugs & Superdrugs - A Focus on Antibacterials

Health systems and medical professionals throughout the world are confronting the challenge of drug resistant bacteria, with regular outbreaks and dozens of deaths a year from MRSA and C. difficile in first world hospitals; and the emergence of new challenges such as the USA:300 strain in San Fransisco. As the focus of the drug industry shifts back towards developing novel antibiotics, SMi’s 11^th Annual Superbugs and Superdrugs conference will provide the perfect opportunity to assess the latest developments in this exciting field.

Why should you attend this event?

Our panel of leading experts from the pharma and biotech industries and academia will look at key topics including: Case studies of novel therapeutics for Helicobacter pylori Developing new treatments for multi drug resistant TB NCEs that target the challenge of gram positive bacteria Clinical challenges in achieving regulatory approval, including paediatric trials Pricing and reimbursement opportunities for antibiotics New screening and detection technologies for drug resistant bacteria

Our expert speaker line-up also includes:

·         David McIntosh, Medical Director, Infectious Diseases (EMEA), Wyeth Europa

·         Chris Thomson, Director, Business Development, Astellas Europe

·         Neil Ryder, Executive Director, Infectious Diseases, Novartis

·         Ronald GM Van Amsterdam, Principal Medical Scientist, Astellas Europe

·         William Wiess, Director of Preclinical Services, Health Science Centre, University of North Texas

·         Harald Labischinski, Chief Scientific Officer, Merlion Pharmaceuticals

·         Richard James, Director, Centre for Healthcare Associated Infections, University of Nottingham

·         Lloyd Czaplewski, Director of Research, Prolysis

·         William Love, Chief Executive Officer, Destiny Pharmaceuticals

·         Alex O’Neill, Independent Research Fellow, Institute of Molecular and Cellular Biology, University of Leeds

·         Albert Collinson, Chief Business Officer, RibX Pharmaceuticals

·         Rick Scott, Vice President, Research, Polymedix

·         Andrew Mearns Spragg, CEO, Aquapharm Biodiscovery

·         Nafsika Georgopapadakou, Vice President, Research, Novabay Pharmaceuticals

·         Scott Parkinson, Research Investigator, Novartis Institutes for Biomedical Research

Who should attend?

Managers, Directors, and Vice Presidents working in: Microbiology Immunology Infectious Diseases Medicinal Chemistry Clinical Pharmacology Drug Discovery New Product Development Scientific Affairs Licensing Antibiotics Infection Discovery Drug evaluation Molecular Biotechnology Drug Development Project Management Preclinical Development Portfolio Management

Last years attendees included representatives of the following companies:

Novo Nordisk Plant Bioscience (PBL) Leo Pharma Summit Arpida Rib-X Pharmaceuticals Enanta Pharmaceuticals AstraZeneca Intermed Discovery Wockhardt University Medical Centre Utrecht Targanta Therapeutics Cipan - Companhia Industiral Produtora De Antibioticos S A Aquapharm Biodiscovery Cilag Biotech AM-Pharma

Enanta Pharmaceuticals Bayer Healthcare Boehringer Ingelheim University of Oxford Forest Laboratories Dr Reddy's Laboratories NOVEXEL Novolytics Destiny Pharma IPSAT Therapies Mutabilis SA Intermed Discovery Anacor Pharmaceuticals Pfizer Combinature Biopharma Meiji Seika Kaisha Pharmaceuticals